Lord, Abbett & Co’s CRISPR Therapeutics CRSP Stock Holding History

Lord, Abbett & Co’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-85,549	Closed	-$5.2M	–	573
2022 Q2	$5.2M	Buy	+85,549	New	+$5.03M	0.02%	488
2021 Q1	–	Sell	-307,320	Closed	-$47.1M	–	649
2020 Q4	$47.1M	Buy	307,320 +14,279	+5%	+$1.69M	0.12%	258
2020 Q3	$24.5M	Buy	293,041 +18,124	+7%	+$1.61M	0.08%	343
2020 Q2	$20.2M	Sell	274,917 -16,457	-6%	-$962K	0.07%	370
2020 Q1	$12.4M	Buy	291,374 +8,940	+3%	+$462K	0.05%	390
2019 Q4	$17.2M	Sell	282,434 -74,587	-21%	-$4.07M	0.06%	424
2019 Q3	$14.6M	Buy	+357,021	New	+$17.1M	0.05%	467
2018 Q3	–	Sell	-225,970	Closed	-$13.3M	–	835
2018 Q2	$13.3M	Buy	+225,970	New	+$12.9M	0.04%	573
2017 Q1	–	Sell	-211,700	Closed	-$4.29M	–	870
2016 Q4	$4.29M	Buy	+211,700	New	+$3.96M	0.01%	764

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lord, Abbett & Co's CRSP Position: Q3 2022 in Review

Lord, Abbett & Co sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 85,549 shares — an estimated $5.2M sold.

Lord, Abbett & Co first reported a position in CRSP in Q4 2016 and held it in 9 quarters. The position peaked at $47.1M in Q4 2020. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

Lord, Abbett & Co reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
Lord, Abbett & Co sold 85,549 CRISPR Therapeutics shares in Q3 2022, an estimated $5.2M.
Lord, Abbett & Co first reported a position in CRISPR Therapeutics in Q4 2016 and held it in 9 quarters.
Lord, Abbett & Co's CRISPR Therapeutics position peaked at $47.1M in Q4 2020.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Lord, Abbett & Co's 13F filing for Q3 2022, filed 14 Nov 2022.